Toggle navigation
Home
Search
Services
Blog
Contact
About
Drug Cross Resistance Patterns in Human Cell Lines
Thilagar, Arulasanam K.
Sitek Research Laboratories, Rockville, MD, United States
Search 10 grants from Arulasanam Thilagar
Search grants from Sitek Research Laboratories
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
PET Imaging of Cortical Dopamine Transmission in Cocaine Addiction
Dynamic ion selectivity of K2P channels and paradoxical depolarization
Regulation of HSV Gene Expression by HCF
Biophysics of Myeloma Pathology
Testosterone Replacement Therapy for Major Depression in Elderly Males
Recently added grants:
Novel bioengineered microRNA therapeutics for lung cancer
The Study of Immune Effects in Gliomas Treated with Oncolytic Viruses in Combination with IDO Inhibitors
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
A New Quality-of-Life Instrument to Assess Functional Outcomes of Cochlear Implantation in Adults
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Small Business Innovation Research – Phase I (N43)
Project #
N43CM057825-000
Application #
3613441
Study Section
Project Start
1985-09-30
Project End
Budget Start
1985-09-30
Budget End
1986-03-31
Support Year
Fiscal Year
1985
Total Cost
Indirect Cost
Institution
Name
Sitek Research Laboratories
Department
Type
DUNS #
City
Rockville
State
MD
Country
United States
Zip Code
20850
Related projects
NIH 1986
N43 CM
Drug Cross Resistance Patterns in Human Cell Lines
Thilagar, Arulasanam K. / Sitek Research Laboratories
NIH 1985
N43 CM
Drug Cross Resistance Patterns in Human Cell Lines
Thilagar, Arulasanam K. / Sitek Research Laboratories
Comments
Be the first to comment on Arulasanam Thilagar's grant